KMH-2 Cells
USD$800.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | KMH-2 is a human anaplastic thyroid carcinoma (ATC) cell line derived from a male patient with a rapidly progressing and fatal form of thyroid cancer. Anaplastic thyroid carcinoma is one of the most aggressive and lethal thyroid malignancies, characterized by its rapid growth and resistance to conventional therapies. KMH-2 cells were established from a biopsy of the primary tumor before the patient underwent any chemotherapy or radiotherapy. These cells are highly relevant for studying the pathophysiology of ATC, as well as for testing the efficacy of new therapeutic agents. The KMH-2 cell line exhibits a spindle-shaped morphology when cultured in vitro, which is typical of many anaplastic thyroid carcinoma cells. These cells have shown resistance to multiple chemotherapeutic agents, including cisplatin, doxorubicin, etoposide, and pepleomycin, reflecting the clinical challenge of treating ATC. The chemoresistance in KMH-2 cells has been attributed to the expression of multidrug resistance-associated protein (MRP) mRNA, although they do not express the mdr-1 and mdr-3 mRNAs associated with P-glycoprotein, suggesting that their drug resistance mechanism is independent of P-glycoprotein. This resistance to chemotherapy makes KMH-2 a valuable model for investigating alternative treatment strategies. In terms of growth characteristics, KMH-2 cells have relatively long doubling times, and their tumorigenicity has been confirmed in xenotransplantation models using athymic nude mice. However, these cells required specific conditions to enhance proliferation in vivo, such as the use of a tiny plastic plate to facilitate growth post-inoculation. Chromosomal analysis of KMH-2 has revealed multiple abnormalities, a common feature in aggressive cancers, which further underscores their utility in studying the genetic underpinnings of anaplastic thyroid carcinoma. |
|---|---|
| Organism | Human |
| Tissue | Thyroid |
| Disease | Thyroid gland anaplastic carcinoma |
| Metastatic site | Pleural effusion |
| Synonyms | KMHDASH2, KMH2 |
Characteristics
| Age | 71 years |
|---|---|
| Gender | Male |
| Ethnicity | Asian |
| Morphology | Spindle shaped cells with giant cells |
| Growth properties | Adherent |
Regulatory Data
| Citation | KMH-2 (Cytion catalog number 305142) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_S641 |
Biomolecular Data
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase |
| Doubling time | 58 hours |
| Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305142-100524 | Certificate of Analysis | 23. May. 2025 | 305142 |